An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Myomo To Participate in the 35th Annual Roth Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Myomo, Inc. (NYSE American: MYO), a leader in wearable medical robotics, will present at the 35th Annual Roth Conference on March 13-14, 2023, at The Ritz-Carlton in Dana Point, California. David Henry, Myomo's CFO, will participate in a 'Fireside Chat' on March 13 at 1:30 p.m. PT. A live webcast of his presentation will be available here and will also be archived on the company's website.
Positive
None.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will presenting at the 35th Annual Roth Conference, March 13-14, 2023 at The Ritz-Carlton, Dana Point, Calif.David Henry, Myomo’s chief financial officer will participate in a “Fireside Chat” on Monday, March 13th at 1:30 p.m. PT and will be available for one-on-one meetings throughout the conference. A live webcast of the presentation will be available here and will also be archived in the Investors section of the Company’s website.
About Myomo
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.